On Wednesday, Goldman Sachs Global Inc., a leading financial institution signed an investment agreement to become a shareholder in Aragen Biocience.
Aragen Bioscience is a leading provider of outsourced discovery, development, and manufacturing services across both large and small molecule platforms.
The investment is to compliment the shares which Goldman Sachs asset management purchased in the company in the form of GVK biosciences from Chryscapital and other investors.
Meanwhile, a media report on Monday shows that ChrysCapital will be selling off its 17 percent stake. Promoters will dilute 16 percent to give one-third of ownership to Goldman Sachs.
Read More: TerViva Raises $54 Million to Invest in Pongamia Trees
In his contribution, the managing...